MORE THAN 80% TIME IN RANGE WITH OPTIMIZED SETTINGS[1]

omnipod 5 automated insulin delivery system

Of real-world Omnipod® 5 users with time in range (TIR) below 70%

53% **do not frequently use the lowest Target Glucose setting[2]**

Lowering Target Glucose significantly improved TIR[2]

12% TIR

Real-world users showed a 12% time in range difference between the lowest and highest Target Glucose setting[3]

This was achieved with no clinically meaningful impact on time below range.[3]

Target Glucose

150 mg/dL vs. 110 mg/dL

I:C Ratio: 1:9 | Correction Factor: 30 mg/dL



Illustration for example only. Not real user data.

Optimize settings

Target Glucose Setting: 110 mg/dL[1]

Insulin-to-carb ratio: I:C Ratio x TDI ≤ 350[1]

Correction factor: ISF x TDI ≤1500 mg/dL[1]

1. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL. Optimized settings: ISF x TDI = 1500 mg/dL, I:C Ratio x TDI ≤350. RF-062025-00014.

Omnipod® 5 autocorrects for highs while helping to protect from lows.[4,5]



Refer to Cari Berget's "Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe" for tips on optimization.

*Most people with T1D will benefit from AID therapy, and the **Omnipod 5 System has been found safe and effective in diverse clinical trial cohorts,** such as those transitioning from multiple daily injection (MDI) therapy and those with high baseline HbA1c, including those who may not count carbohydrates or bolus consistently."*

—Berget C, et al.

*Bolusing with the Omnipod 5 System is recommended for meals

References:

1. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL. Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014. **2.** Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, Netherlands. Impact of Lowering Target Glucose Setting with the Omnipod 5 Automated Insulin Delivery System: Real-world data from 403 type 1 diabetes (T1D) users who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Omnipod 5 results based on users with ≥90 days CGM data and ≥75% of days with ≥220 readings available. Insulet Data on File. 06.27.25. RF-062025-00038 **3.** Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Real-world data from 403 people with type 1 diabetes aged 2+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range 70-180 mg/dL improved 11.8% ($p<0.05$). Median time <70 mg/dL +0.23% ($p<0.05$). Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Insulet Data on file. 05.15.25. RF-042025-00013 **4.** Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, $P<0.0001$, respectively. Mean time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.9% vs. 1.3%, $P<0.0001$; 2.2% vs. 1.8%, $P=0.8153$, respectively. Results measured by CGM. Study funded by Insulet. **5.** Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, $P<0.0001$. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.43%, 3-mo Omnipod 5 = 2.46%, $P=0.0204$. Results measured by CGM. Study funded by Insulet.

omnipod® 5 automated insulin delivery system

GEFFEN MEDICAL גפן מדיקל

Insulet Netherlands BV • WTC Utrecht Stadsplateau 7, AZ-Utrecht, NL-3521 Netherlands •

Insulet Netherlands, B.V, Stadsplateau 7, 3521 AZ Utrecht, Netherland

INS-OHS-01-2026-00109

Omnipod® 5 System Availability Guide

Please contact a **Geffen Medical** representative for more information